Vedanta Biosciences Launches Phase 3 Trial for Recurrent C. Diff Prevention

The RESTORATiVE303 study will evaluate VE303 to prevent recurring Clostridioides difficile infections.

Apr. 2, 2026 at 10:30pm

Got story updates? Submit your updates here. ›

A translucent, ghostly X-ray image revealing the intricate web-like structure of the human gut microbiome, conveying the clinical and scientific nature of a new treatment for recurrent C. diff infections.A novel treatment aims to restore the delicate balance of the gut microbiome and prevent recurrent Clostridioides difficile infections.Cambridge Today

Vedanta Biosciences, a clinical-stage microbiome company, has announced the start of the Phase 3 RESTORATiVE303 study to evaluate its investigational drug VE303 for the prevention of recurrent Clostridioides difficile (C. diff) infection. The multicenter, randomized, double-blind, placebo-controlled trial will assess the safety and efficacy of VE303 in adults who have experienced at least one prior episode of C. diff infection.

Why it matters

C. diff is a serious and potentially life-threatening bacterial infection that often recurs, making prevention a critical unmet need. Vedanta's VE303 is a novel, orally administered investigational live biotherapeutic product designed to restore the gut microbiome and prevent C. diff recurrence.

The details

The RESTORATiVE303 study will enroll approximately 1,200 adults who have experienced at least one prior episode of C. diff infection. Participants will be randomized to receive either VE303 or a placebo, with the primary endpoint being the prevention of C. diff recurrence within 24 weeks.

  • The study is currently underway and is expected to be completed in 2028.

The players

Vedanta Biosciences

A clinical-stage microbiome company developing novel live biotherapeutic products to treat and prevent a range of diseases.

VE303

Vedanta's investigational live biotherapeutic product designed to restore the gut microbiome and prevent recurrent Clostridioides difficile infection.

Got photos? Submit your photos here. ›

What’s next

The results of the RESTORATiVE303 study will determine the next steps for VE303's development and potential regulatory approval for the prevention of recurrent C. diff infection.

The takeaway

The launch of this Phase 3 trial represents an important milestone in the development of a much-needed treatment to address the significant public health challenge posed by recurrent C. diff infections.